Contact Us
Drug Search Results
More Filters [+]

Laropiprant

Alternative Names: laropiprant, mk-0524b, mk-0524, mk0524, mk 0524
Latest Update: 2023-08-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CRTH2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hungary | India | Ireland | Italy | New Zealand | Russia | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Laropiprant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemia|Hyperlipidemia|Type 2 Diabetes|Coronary Artery Disease|Atherosclerosis|Inflammation|Myocardial Ischemia|Oxidative Stress

Phase 3: Dyslipidemia|Hypercholesterolemia|Type 2 Diabetes|Stroke|Hyperlipidemia|Myocardial Infarction|Intermittent Claudication|Peripheral Arterial Disease|Coronary Disease|Coronary Artery Disease|Hyperlipoproteinemias|Lipidoses|Hyperlipoproteinemia Type V|Hyperlipoproteinemia Type II|Myocardial Ischemia|Peripheral Vascular Diseases

Phase 2: Dyslipidemia|Hypercholesterolemia|Rhinitis, Allergic, Seasonal|Asthma|Flushing

Phase 1: Hypercholesterolemia|Hyperlipidemia|Type 2 Diabetes|Dyslipidemia|Hyperlipoproteinemia Type II|Rosacea

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NILACH

P4

Terminated

Atherosclerosis

2014-07-01

MK-0524A-119

N/A

Terminated

Hypercholesterolemia|Dyslipidemia

2013-05-01

2011-000755-17

P3

Terminated

Coronary Disease

2013-03-08

MK-0524A-133

P3

Terminated

Hypercholesterolemia|Dyslipidemia

2013-02-26

Recent News Events

Date

Type

Title

08/01/2023

PubMed

 A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.

03/18/2022

PubMed

 Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation.

10/01/2021

News Article

 Niacin and Niacinamide Market Projected to Grow at a CAGR of 5.8% During the Forecast Period 2021-2026

01/01/2021

PubMed

 Prostaglandin D2 contributes to cisplatin-induced neuropathic pain in rats via DP2 receptor in the spinal cord.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions